Previous 10 | Next 10 |
The Medicines Company (NASDAQ: MDCO) announced last week that recent trial data showed positive results for its flagship cholesterol drug , inclisiran. Shares of the company, which has a $3.82 billion market cap, shot up 9.3% in response to the news, and although the stock has given back mo...
The Medicines Company (NASDAQ: MDCO) is up 161% this year, thanks in large part to the success of its cholesterol-lowering drug inclisiran. In August, the company announced that one of its late-stage clinical trials, Orion-11, was positive, which was followed by a presentation a few days ...
The Medicines Company (NASDAQ: MDCO ) announces positive results from two Phase 3 clinical trials for inclisiran. Both studies met all primary and secondary endpoints with no new safety signals reported. Detailed data will be presented at the American Heart Association Scientific Sessions in...
ORION-10 study met all primary and secondary endpoints, with durable and potent efficacy and excellent safety of inclisiran that were at least as favorable as observed in ORION-11 ORION-10 completion marks successful conclusion of pivotal Phase 3 LDL-C lowering studies of in...
ORION-9 study met all primary and secondary efficacy endpoints Inclisiran demonstrated durable and potent efficacy and excellent safety in a patient population where cardiovascular disease is most severe Detailed data from ORION-9 will be presented in a late-breaki...
Cellular Biomedicine Group (NASDAQ: CBMG ) initiated with Buy rating and $19 (28% upside) price target at BTIG Research. More news on: Cellular Biomedicine Group, Inc., Lexaria Bioscience Corp., Orchard Therapeutics plc, Healthcare stocks news, , Stocks on the move, Read more ...
After the Federal Trade Commission (FTC) demanded Bristol-Myers Squibb (NYSE: BMY) sell its blockbuster Otezla to secure approval for its $74 billion acquisition of Celgene (NASDAQ: CELG) , a bidding war resulted in Amgen (NASDAQ: AMGN) agreeing to pay $13.4 billion in cash for the ps...
Concerns about the effect of the trade war on the economy deepened Tuesday after new tariffs went in place over the weekend and a report showed that U.S. factory activity in August contracted for the first time in three years. The Dow Jones Industrial Average (DJINDICES: ^DJI) ...
Shares of The Medicines Company (NASDAQ: MDCO) , a biopharmaceutical company focused on lowering cholesterol, are on the move again following yesterday's presentation of the Orion-11 trial results. Healthcare-minded investors pleased with the details drove the stock 10.4% higher on Tuesday....
Tuesday was a bad day on Wall Street, as investors reacted negatively to new tariffs that went into effect between the U.S. and China. Many market participants had hoped that the two parties would agree to some kind of temporary reprieve to avoid the uptick in trade tensions, but it now appears ...
News, Short Squeeze, Breakout and More Instantly...
The Medicines Company Company Name:
MDCO Stock Symbol:
NASDAQ Market:
The Medicines Company Website:
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 3...
Shares of Meritor (NYSE: MTOR) , a global supplier of drivetrain, braking, and other aftermarket automotive solutions for vehicles, jumped as high as 16% Tuesday morning after markets digested the announcement that Meritor will join the S&P SmallCap 600 index. The announcement actually c...
NEW YORK , Dec. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the open of trading on Monday, January 6 : NexPoint Residential Trust Inc. (NYSE: NXRT) will replace Avon Products Inc. (NYSE: AVP). Natura...